This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (36)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Nancy Odaka, MHS; Lois Eldred, MPH; Sylvia Cohn, MPH; Alvaro Muñoz, PhD; Howard A. Fields, PhD; Robin Fox, MS; Rachel Solomon, MHS; Richard Kaslow, MD; B. Frank Polk, MD

JAMA. 1988;260(24):3635-3637.

Abstract
A randomized, double-blind clinical trial of plasma-derived and DNA recombinant hepatitis B virus vaccines was conducted in 186 homosexual men. Nine months after the immunization series (three doses) began, the seroconversion rate in the plasma vaccine group was 88% (68/77); this was significantly higher than the 74% (60/81) response rate of the recombinant vaccine group. Men positive for antibody to the human immunodeficiency virus (HIV) had a considerably higher nonresponse rate to either vaccine than expected in non—HIV-infected homosexual men. The odds ratios of nonresponse to hepatitis B virus vaccine for HIV-seropositive vs HIV-seronegative subjects were 12.0 (95% confidence interval, 1.7to 89.3) and 13.6 (95% confidence interval, 2.3 to 148.3) for the plasma and DNA recombinant vaccines, respectively.

(JAMA 1988;260:3635-3637)

Author Affiliations
From The Johns Hopkins University School of Hygiene and Public Health, Baltimore (Mss Odaka, Eldred, Cohn, and Fox and Dr Muñoz); the Hepatitis Branch, Centers for Disease Control, Atlanta (Dr Fields); and the National Institute of Allergy and Infectious Diseases, Bethesda, Md (Ms Solomon and Dr Kaslow).

Footnotes
Dr Polk died Oct 11,1988.

Reprint requests to The Johns Hopkins University School of Hygiene and Public Health, 550 N Broadway, Suite 701, Baltimore, MD 21205 (Ms Odaka).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Use of Licensed Vaccines for Active Immunization of the Immunocompromised Host
Pirofski and Casadevall
Clin. Microbiol. Rev. 1998;11:1-26.
ABSTRACT | FULL TEXT  

Screening for Hepatocellular Carcinoma in High-Risk Individuals: A Clinical Review
Regan
Arch Intern Med 1989;149:1741-1744.
ABSTRACT